1) Although the bi-national Swedish Danish Medicon Valley cluster is explicitly highlighted in the Draghi-report, it does not feature prominently in the national Swedish life science strategy. Why do you think that is?
The Medicon Valley cluster is undoubtedly a key asset for Nordic and European life science. While it is clearly recognized in international analyses like the Draghi report, national strategies often focus on internal structures, regional development, national investments, and local innovation ecosystems. The Swedish life science strategy highlights Nordic collaboration as key to having impact on international policy and global attractiveness. Given the current geopolitical situation, tariffs and the US Most-Favored-Nation pricing policy on pharmaceuticals, the Nordics joining forces is more important than ever. We see growing awareness of the cluster’s importance, and stronger integration of cross-border initiatives.
2) Objectively, Sweden and Denmark are the leading life science nations in the Nordics. In some respects, the countries compete, but where do you see potential for further collaboration?
There is far more to gain from collaboration than from competition. Both countries share strong research environments, advanced healthcare systems, and globally competitive companies. Areas with particularly strong potential for collaboration include:
- Data sharing and health registries: Harmonizing legal and ethical frameworks to enable joint use of health data.
- Clinical trials infrastructure: Creating a joint platform that positions the region as a preferred destination for international trials.
- Skills development and mobility: Promoting cross-border mobility of researchers and professionals to build a stronger regional talent pool.
A deeper integration would not only benefit both nations, but also elevate the region’s standing in global life science.
3) If you were asked for 3 specific pieces of input for a joint European life science strategy, what would you suggest?
- Utilize the Nordic experience and organize effective governance through a dedicated Life Sciences Office. Establish EU-wide standards for access, interoperability, and ethical use of health data—ensuring patient trust and accelerating innovation.
- Facilitate access to groundbreaking innovations and investment in cross-border infrastructure. Prioritize and speed up implementation of new innovative pharmaceuticals. Support collaborative ecosystems like Medicon Valley, with targeted EU funding for shared R&D platforms, manufacturing capabilities, and clinical trial networks.
- Strengthening Europe’s global competitiveness: Secure IP and focused initiatives to retain life science innovation within Europe—through incentives for advanced research, public-private partnerships, and streamlined pathways from discovery to market.